Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    The Estate by sbe Announces Today: The Future of Living with Over $1 Billion in Branded Luxury Residential Development

    November 18, 2026

    IGEL Reaches Unicorn Status with Strategic Investment from Vitruvian Partners to Accelerate Growth of its Endpoint Security and Cyber Resilience Endpoint Platform for Enterprise

    November 18, 2026

    Andela is Named a Select Tier Services Partner in the Claude Partner Network

    November 18, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Benghazi DailyBenghazi Daily
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Benghazi DailyBenghazi Daily
    Home » Korea to receive 40 million COVID vaccines from Moderna
    Health

    Korea to receive 40 million COVID vaccines from Moderna

    March 4, 2021

    Moderna Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, confirmed that the Company has entered into a supply agreement with the government of the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine to support the government’s aim of providing vaccines to the public as soon as possible. Under the terms of the proposed agreement, deliveries would begin in May 2021.

    Korea to receive 40 million COVID vaccines from Moderna
    Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. 

    The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

    Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit their website.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Health

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026
    Health

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026
    Health

    WHO reports 67 yellow fever cases in nine African countries

    November 7, 2026
    Latest News

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026

    UAE President and Venezuela’s acting leader discuss closer ties

    November 17, 2026

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    UAE and Timor-Leste presidents discuss stronger bilateral ties

    November 16, 2026

    UAE President, Arab League chief discuss regional security

    November 14, 2026

    Morocco secures €434.4 million AfDB loan for reforms

    November 14, 2026
    © 2026 Benghazi Daily | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.